Nakiller Listesi
Filter by:
| No. | Cell source | Indication | Area of medicine | Year | Type of therapy | Country | Age |
|---|---|---|---|---|---|---|---|
| 1 | cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2.2 |
| 2 | cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5.4 |
| 3 | cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 10.3 |
| 4 | cord blood | autism | neurology | 2017 | experimental therapy | Poland | 4.11 |
| 5 | cord blood | CD40 ligand deficiency | hematology | 2017 | standard therapy | Turkey | 9.6 |
| 6 | cord blood | talassemia major | hematology | 2017 | standard therapy | Turkey | 4.0 |
| 7 | cord blood | talassemia major | hematology | 2017 | standard therapy | Turkey | 4.1 |
| 8 | cord blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Hungary | 7 |
| 9 | cord blood | acute myeloid leukemia | hematology | 2016 | standard therapy | Jordan | 6 |
| 10 | cord blood | autism | neurology | 2016 | experimental therapy | Poland | 6 |
| 11 | cord blood | acute lymphoblastic leukemia | hematology | 2015 | standard therapy | Poland | 4 |
| 12 | cord blood | acute lymphoblastic leukemia | hematology | 2014 | standard therapy | Turkey | 7 |
| 13 | cord blood | aplastic anaemia | hematology | 2013 | standard therapy | Poland | 3 |
| 14 | cord blood | acute myeloid leukemia | hematology | 2013 | standard therapy | Poland | 3 |
| 15 | cord blood | X - linked lymphoproliferative syndrome | hematology | 2013 | standard therapy | Poland | 10/12 |
| 16 | cord blood | beta-talassemia; agranulocytosis | hematology | 2013 | standard therapy | Turkey | 8 |
| 17 | cord blood | severe aplastic anaemia | hematology | 2012 | standard therapy | Hungary | 3 |
| 18 | cord blood | anaemia, talassemia major | hematology | 2012 | standard therapy | Turkey | 6 |
| 19 | cord blood | talassemia major, acute lymphoblastic leukemia | hematology | 2012 | standard therapy | Turkey | 3.5 |
| 20 | cord blood | T-acute lymphoblastic leukemia | hematology | 2012 | standard therapy | Turkey | 5 |
| 21 | cord blood | acute myeloid leukemia | hematology | 2011 | standard therapy | Hungary | 2 |
| 22 | cord blood | Fanconi anemia | hematology | 2011 | standard therapy | Poland | 12 |
| 23 | cord blood | acute lymphoblastic leukemia | hematology | 2011 | standard therapy | Poland | 5 |
| 24 | cord blood | histiocytosis | hematology | 2011 | standard therapy | Poland | 2.5 |
| 25 | cord blood | chronic granulomatous disease | hematology | 2011 | standard therapy | Poland | 7.5 |
| 26 | cord blood | pre -B acute lymphoblastic leukemia | hematology | 2010 | standard therapy | Hungary | 1.5 |
| 27 | cord blood | myelodysplastic syndrome | hematology | 2009 | standard therapy | Poland | 5 |
| 28 | cord blood | acute lymphoblastic leukemia | hematology | 2008 | standard therapy | Poland | 5 |
| 29 | cord blood | cerebral ischemia | neurology | 2008 | experimental therapy | Poland | 1.5 |
| 30 | cord blood | neuroblastoma | hematology | 2007 | standard therapy | Poland | 8 |
| 31 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 67.11 |
| 32 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 47.6 |
| 33 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 56.7 |
| 34 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 48.11 |
| 35 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 46.3 |
| 36 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 45.9 |
| 37 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 75.9 |
| 38 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 51.3 |
| 39 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 59.8 |
| 40 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 64.9 |
| 41 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 56.7 |
| 42 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | olsztyn | 69.10 |
| 43 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 52.0 |
| 44 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 77.2 |
| 45 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 35.6 |
| 46 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 51.6 |
| 47 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Olsztyn | 46.0 |
| 48 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2.10 |
| 49 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 37.9 |
| 50 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 71.7 |
| 51 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | no data |
| 52 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7.11 |
| 53 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 44.1 |
| 54 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 34.11 |
| 55 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 58.10 |
| 56 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 49.0 |
| 57 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 37.4 |
| 58 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 37.7 |
| 59 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 26.11 |
| 60 | cord tissue (Wharton's jelly) | cartilage damage | orthopedics | 2017 | experimental therapy | Poland | 61.5 |
| 61 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 34.1 |
| 62 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 52.9 |
| 63 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2017 | experimental therapy | Poland | 23.9 |
| 64 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 31.6 |
| 65 | cord tissue (Wharton's jelly) | age-related macular degeneration | ophthalmology | 2017 | experimental therapy | Poland | 33.4 |
| 66 | cord tissue (Wharton's jelly) | tetraparesis spastica | neurology | 2017 | experimental therapy | Poland | 29.4 |
| 67 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 24.9 |
| 68 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 10.6 |
| 69 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 30.0 |
| 70 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 56.8 |
| 71 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 65.2 |
| 72 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2017 | experimental therapy | Poland | 28.6 |
| 73 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 44.2 |
| 74 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 41.4 |
| 75 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 25.8 |
| 76 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 23.7 |
| 77 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 43.4 |
| 78 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 39.0 |
| 79 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 39.0 |
| 80 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 42.11 |
| 81 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 30.9 |
| 82 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 12.11 |
| 83 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 8.5 |
| 84 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2017 | experimental therapy | Poland | 58.9 |
| 85 | cord tissue (Wharton's jelly) | cri du chat syndrome | neurology | 2017 | experimental therapy | Poland | 8.6 |
| 86 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 18.7 |
| 87 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 22.1 |
| 88 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2017 | experimental therapy | Poland | 28.11 |
| 89 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2017 | experimental therapy | Poland | 3.1 |
| 90 | cord tissue (Wharton's jelly) | cranium bifidum | neurology | 2017 | experimental therapy | Poland | 5.2 |
| 91 | cord tissue (Wharton's jelly) | transverse myelitis | neurology | 2017 | experimental therapy | Poland | 8.3 |
| 92 | cord tissue (Wharton's jelly) | syringomielia | neurology | 2017 | experimental therapy | Poland | 42.6 |
| 93 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 47.2 |
| 94 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 38.5 |
| 95 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 13.4 |
| 96 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2017 | experimental therapy | Poland | 21.10 |
| 97 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2017 | experimental therapy | Poland | 5.0 |
| 98 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 41.0 |
| 99 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 52.1 |
| 100 | cord tissue (Wharton's jelly) | cerebral palsy; neonatal cerebral leukomalacia | neurology | 2017 | experimental therapy | Poland | 1.9 |
| 101 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 11.11 |
| 102 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 26.10 |
| 103 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 9.1 |
| 104 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 11.5 |
| 105 | cord tissue (Wharton's jelly) | congenital fiber-type disproportion myopathy | neurology | 2017 | experimental therapy | Poland | 1.10 |
| 106 | cord tissue (Wharton's jelly) | chronic myeloid leukemia | hematology | 2017 | experimental therapy | Poland | 5.11 |
| 107 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 61.5 |
| 108 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 40.11 |
| 109 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 48.1 |
| 110 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 1.11 |
| 111 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 37.11 |
| 112 | cord tissue (Wharton's jelly) | arthrogryposis multiplex congenita | neurology | 2017 | experimental therapy | Poland | 1.7 |
| 113 | cord tissue (Wharton's jelly) | encephalopathy; cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4.4 |
| 114 | cord tissue (Wharton's jelly) | cerebral palsy; epilepsy | neurology | 2017 | experimental therapy | Poland | 5.8 |
| 115 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 6.4 |
| 116 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 15.4 |
| 117 | cord tissue (Wharton's jelly) | traumatic brain injury | neurology | 2017 | experimental therapy | Poland | 9.4 |
| 118 | cord tissue (Wharton's jelly) | no bone adhesion | orthopedics | 2017 | experimental therapy | Poland | 14.1 |
| 119 | cord tissue (Wharton's jelly) | no bone adhesion | orthopedics | 2017 | experimental therapy | Poland | 17.11 |
| 120 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 24.9 |
| 121 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 37.7 |
| 122 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 31.1 |
| 123 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 52.11 |
| 124 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 27.11 |
| 125 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 45.4 |
| 126 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 34.10 |
| 127 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 31.6 |
| 128 | cord tissue (Wharton's jelly) | hydrocephalus; neonatal cerebral leukomalacia | neurology | 2017 | experimental therapy | Poland | 2.3 |
| 129 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 6.3 |
| 130 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7.11 |
| 131 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 3.5 |
| 132 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 6.3 |
| 133 | cord tissue (Wharton's jelly) | syndrom IFAP | hematology | 2017 | experimental therapy | Poland | 3.5 |
| 134 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 13.0 |
| 135 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 11.10 |
| 136 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 66.11 |
| 137 | cord tissue (Wharton's jelly) | ischemia within the optic nerve | ophthalmology | 2017 | experimental therapy | Poland | 37.11 |
| 138 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 35.1 |
| 139 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4.11 |
| 140 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 36.11 |
| 141 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 63.11 |
| 142 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 31.9 |
| 143 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 31.9 |
| 144 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 10.2 |
| 145 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 33.5 |
| 146 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5.7 |
| 147 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 12.5 |
| 148 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5.9 |
| 149 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3.3 |
| 150 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 5.0 |
| 151 | cord tissue (Wharton's jelly) | hypoxia-ischemic encephalopathy | neurology | 2017 | experimental therapy | Poland | 1.9 |
| 152 | cord tissue (Wharton's jelly) | Krabbe disease | neurology | 2017 | experimental therapy | Poland | 6.3 |
| 153 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 24.6 |
| 154 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 45.5 |
| 155 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 31.5 |
| 156 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 48.10 |
| 157 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 62.5 |
| 158 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 60.5 |
| 159 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 6.1 |
| 160 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 4.8 |
| 161 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 6.4 |
| 162 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 6.3 |
| 163 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 49.1 |
| 164 | cord tissue (Wharton's jelly) | condition after encephalitis | neurology | 2017 | experimental therapy | Poland | 19.7 |
| 165 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 35.4 |
| 166 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 1.10 |
| 167 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 6.8 |
| 168 | cord tissue (Wharton's jelly) | encephalopathy; cerebral palsy | neurology | 2017 | experimental therapy | Poland | 1.5 |
| 169 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7.0 |
| 170 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 13.6 |
| 171 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 6.7 |
| 172 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 32.3 |
| 173 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 46.9 |
| 174 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 54.10 |
| 175 | cord tissue (Wharton's jelly) | dystrophia myotonica | neurology | 2017 | experimental therapy | Poland | 41.11 |
| 176 | cord tissue (Wharton's jelly) | global developmental delay | neurology | 2017 | experimental therapy | Poland | 4.7 |
| 177 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2017 | experimental therapy | Poland | 56.4 |
| 178 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 4.1 |
| 179 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 3.6 |
| 180 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 33.4 |
| 181 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 42.1 |
| 182 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 63.2 |
| 183 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 54.11 |
| 184 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 53.9 |
| 185 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 46.9 |
| 186 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 58 |
| 187 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55 |
| 188 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 58.1 |
| 189 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 61.7 |
| 190 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 52.6 |
| 191 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 59.11 |
| 192 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 66.9 |
| 193 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 45.1 |
| 194 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 53.4 |
| 195 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 36.1 |
| 196 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 59, 1 |
| 197 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 66.2 |
| 198 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 49.7 |
| 199 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55.1 |
| 200 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 46.1 |
| 201 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 72.4 |
| 202 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 54.3 |
| 203 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 56.1 |
| 204 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 61.8 |
| 205 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 64.7 |
| 206 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 62.8 |
| 207 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 56.5 |
| 208 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 51.3 |
| 209 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 60.4 |
| 210 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 73.7 |
| 211 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 61.6 |
| 212 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 61.4 |
| 213 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 79.2 |
| 214 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 72.6 |
| 215 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 48.4 |
| 216 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 54.2 |
| 217 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 50.9 |
| 218 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55.9 |
| 219 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 62.6 |
| 220 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 66.2 |
| 221 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55.9 |
| 222 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 49.4 |
| 223 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55.7 |
| 224 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 58.1 |
| 225 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 66.8 |
| 226 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 39.6 |
| 227 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 47.11 |
| 228 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 49.3 |
| 229 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 61.2 |
| 230 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 65.9 |
| 231 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 52.7 |
| 232 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 71.5 |
| 233 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 68.5 |
| 234 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 44.5 |
| 235 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 66.7 |
| 236 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 51.9 |
| 237 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 49.3 |
| 238 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55.4 |
| 239 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 41.2 |
| 240 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 72.1 |
| 241 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 56.8 |
| 242 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 48.1 |
| 243 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 56.3 |
| 244 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 66.10 |
| 245 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | no data |
| 246 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 60.8 |
| 247 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 55.5 |
| 248 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Olsztyn | 53.4 |
| 249 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10.11 |
| 250 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 44.5 |
| 251 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 60.8 |
| 252 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 32.2 |
| 253 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 64 |
| 254 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 62.5 |
| 255 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 18.4 |
| 256 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 48.8 |
| 257 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10.3 |
| 258 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 35.3 |
| 259 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 53.7 |
| 260 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 12.2 |
| 261 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2016 | experimental therapy | Poland | 3.10 |
| 262 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 14 |
| 263 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 6 |
| 264 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 65.8 |
| 265 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2016 | experimental therapy | Poland | 2.9 |
| 266 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 59.4 |
| 267 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6 |
| 268 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2.11 |
| 269 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 12.11 |
| 270 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 9.7 |
| 271 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2016 | experimental therapy | Poland | 20.3 |
| 272 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2016 | experimental therapy | Poland | 53 |
| 273 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 33.5 |
| 274 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 22.2 |
| 275 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10.3 |
| 276 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 8.5 |
| 277 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 29.11 |
| 278 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 33.4 |
| 279 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 37.4 |
| 280 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 39.3 |
| 281 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 7.11 |
| 282 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 28 |
| 283 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 69.6 |
| 284 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 33.11 |
| 285 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 20.7 |
| 286 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 24.5 |
| 287 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 25.6 |
| 288 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 8.5 |
| 289 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 39.10 |
| 290 | cord tissue (Wharton's jelly) | patella cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 60.10 |
| 291 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6.9 |
| 292 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 44.8 |
| 293 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 25.4 |
| 294 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 10.10 |
| 295 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2016 | experimental therapy | Poland | 19.2 |
| 296 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 28.8 |
| 297 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 60.9 |
| 298 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 34.9 |
| 299 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 69.3 |
| 300 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 47.9 |
| 301 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 18.8 |
| 302 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2.9 |
| 303 | cord tissue (Wharton's jelly) | traumatic brain injury | neurology | 2016 | experimental therapy | Poland | 54.9 |
| 304 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 19.5 |
| 305 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 59 |
| 306 | cord tissue (Wharton's jelly) | tetraparesis | orthopedics | 2016 | experimental therapy | Poland | 27.9 |
| 307 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 14.9 |
| 308 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 42.7 |
| 309 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 60.5 |
| 310 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6.2 |
| 311 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 11.3 |
| 312 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 9.11 |
| 313 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 49.8 |
| 314 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2016 | experimental therapy | Poland | 69.9 |
| 315 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2016 | experimental therapy | Poland | 69.1 |
| 316 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 13.11 |
| 317 | cord tissue (Wharton's jelly) | malformation syndrome | neurology | 2016 | experimental therapy | Poland | 3.5 |
| 318 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 64.2 |
| 319 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 38 |
| 320 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6.10 |
| 321 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2016 | experimental therapy | Poland | 2.11 |
| 322 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 4.2 |
| 323 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 55.4 |
| 324 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 54.8 |
| 325 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 33.10 |
| 326 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 41.4 |
| 327 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 49.3 |
| 328 | cord tissue (Wharton's jelly) | choroideremia | ophthalmology | 2016 | experimental therapy | Poland | 50.8 |
| 329 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 63.1 |
| 330 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 7.4 |
| 331 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2016 | experimental therapy | Poland | 2.11 |
| 332 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 48.3 |
| 333 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 32.7 |
| 334 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 3.11 |
| 335 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 61.11 |
| 336 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 45.8 |
| 337 | cord tissue (Wharton's jelly) | adrenoleukodystrophy | neurology | 2016 | experimental therapy | Poland | 6.11 |
| 338 | cord tissue (Wharton's jelly) | adrenoleukodystrophy | neurology | 2016 | experimental therapy | Poland | 9.7 |
| 339 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 22 |
| 340 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 14.7 |
| 341 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 58.10 |
| 342 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 12.6 |
| 343 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 4.8 |
| 344 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 1.5 |
| 345 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 3 |
| 346 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 9.9 |
| 347 | cord tissue (Wharton's jelly) | global developmental delay | neurology | 2016 | experimental therapy | Poland | 6.9 |
| 348 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 13.2 |
| 349 | cord tissue (Wharton's jelly) | developmental delay | neurology | 2016 | experimental therapy | Poland | 7.4 |
| 350 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 7.4 |
| 351 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2016 | experimental therapy | Poland | 66 |
| 352 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 38.1 |
| 353 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 8.4 |
| 354 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 3 |
| 355 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2016 | experimental therapy | Poland | 79.8 |
| 356 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 54.3 |
| 357 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 14.4 |
| 358 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 23.6 |
| 359 | cord tissue (Wharton's jelly) | age-related macular degeneration | ophthalmology | 2016 | experimental therapy | Poland | 86.5 |
| 360 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 54.6 |
| 361 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 68.5 |
| 362 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 13.7 |
| 363 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2.2 |
| 364 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 5.0 |
| 365 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 12.11 |
| 366 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 12.3 |
| 367 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 1.3 |
| 368 | cord tissue (Wharton's jelly) | developmental delay | neurology | 2016 | experimental therapy | Poland | 2.7 |
| 369 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 3.3 |
| 370 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 59.6 |
| 371 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 34.2 |
| 372 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 30.3 |
| 373 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 17.10 |
| 374 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 37.11 |
| 375 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 31.9 |
| 376 | cord tissue (Wharton's jelly) | ataxia hereditaria | neurology | 2016 | experimental therapy | Poland | 69 |
| 377 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 31.9 |
| 378 | cord tissue (Wharton's jelly) | no data | ophthalmology | 2016 | experimental therapy | Poland | 66.1 |
| 379 | cord tissue (Wharton's jelly) | patella cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 60.8 |
| 380 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10.8 |
| 381 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2016 | experimental therapy | Poland | 3 |
| 382 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 2.11 |
| 383 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2016 | experimental therapy | Poland | 4.3 |
| 384 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | no data |
| 385 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 59.4 |
| 386 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2016 | experimental therapy | Poland | 20.11 |
| 387 | cord tissue (Wharton's jelly) | patella cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 53 |
| 388 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 24.5 |
| 389 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 34, 7 |
| 390 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 32.3 |
| 391 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 60.7 |
| 392 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 1.10 |
| 393 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 7.6 |
| 394 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 1.10 |
| 395 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 29.7 |
| 396 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2016 | experimental therapy | Poland | 8/12 |
| 397 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 9.2 |
| 398 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2016 | experimental therapy | Poland | 24.5 |
| 399 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 15.9 |
| 400 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 6.8 |
| 401 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 10.3 |
| 402 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 16.4 |
| 403 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6 |
| 404 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 41.8 |
| 405 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 20.9 |
| 406 | cord tissue (Wharton's jelly) | fetal alcohol spectrum disorders | neurology | 2016 | experimental therapy | Poland | 5.2 |
| 407 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 13.10 |
| 408 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 58.4 |
| 409 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 68.2 |
| 410 | cord tissue (Wharton's jelly) | chondronecrosis femoral condyle | orthopedics | 2016 | experimental therapy | Poland | 54.11 |
| 411 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 2.1 |
| 412 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 18 |
| 413 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 4.1 |
| 414 | cord tissue (Wharton's jelly) | gangliosidosis t. 1 | neurology | 2016 | experimental therapy | Poland | 1.4 |
| 415 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 14.9 |
| 416 | cord tissue (Wharton's jelly) | epileptic encephalopathy | neurology | 2016 | experimental therapy | Poland | 3.6 |
| 417 | cord tissue (Wharton's jelly) | polineuropathy | neurology | 2016 | experimental therapy | Poland | 70.8 |
| 418 | cord tissue (Wharton's jelly) | diffuse cartilage damage left medial compartment of the knee | orthopedics | 2016 | experimental therapy | Poland | 50.5 |
| 419 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2016 | experimental therapy | Poland | 37.7 |
| 420 | cord tissue (Wharton's jelly) | myopia, hyperopia, astigmatism, abnormal refraction and accommodation, optic atrophy | ophthalmology | 2016 | experimental therapy | Poland | 37.1 |
| 421 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2016 | experimental therapy | Poland | 33.5 |
| 422 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 16.2 |
| 423 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 3.7 |
| 424 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 17.9 |
| 425 | cord tissue (Wharton's jelly) | injuries to the spinal nerves | neurology | 2016 | experimental therapy | Poland | 5/12 |
| 426 | cord tissue (Wharton's jelly) | cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 57.6 |
| 427 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 4.8 |
| 428 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 44.7 |
| 429 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 10 |
| 430 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 4.4 |
| 431 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 4.9 |
| 432 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2016 | experimental therapy | Poland | 28.6 |
| 433 | cord tissue (Wharton's jelly) | neurodevelopmental disorders | neurology | 2016 | experimental therapy | Poland | 4.5 |
| 434 | cord tissue (Wharton's jelly) | tetraparesis | orthopedics | 2016 | experimental therapy | Poland | 27.2 |
| 435 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61.2 |
| 436 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 44.8 |
| 437 | cord tissue (Wharton's jelly) | degeneration of the cartilage of the knee joint | orthopedics | 2016 | experimental therapy | Poland | 54.3 |
| 438 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /BMD | neurology | 2016 | experimental therapy | Poland | 19.2 |
| 439 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 15.0 |
| 440 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 31.11 |
| 441 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 33.4 |
| 442 | cord tissue (Wharton's jelly) | endometrial atrophy | ginecology | 2016 | experimental therapy | Poland | 37.3 |
| 443 | cord tissue (Wharton's jelly) | endometrial atrophy | ginecology | 2016 | experimental therapy | Poland | 39.1 |
| 444 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 38.4 |
| 445 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 44.5 |
| 446 | cord tissue (Wharton's jelly) | meniscus damage | orthopedics | 2016 | experimental therapy | Poland | 35.5 |
| 447 | cord tissue (Wharton's jelly) | premature ovarian failure | ginecology | 2016 | experimental therapy | Poland | 23.4 |
| 448 | cord tissue (Wharton's jelly) | premature ovarian failure | ginecology | 2016 | experimental therapy | Poland | 34.9 |
| 449 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 61.6 |
| 450 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 61 |
| 451 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 56 |
| 452 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 51 |
| 453 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 65 |
| 454 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 60 |
| 455 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Olsztyn | 52 |
| 456 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 1.4 |
| 457 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 5.4 |
| 458 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2015 | experimental therapy | Poland | 23.2 |
| 459 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 3.8 |
| 460 | cord tissue (Wharton's jelly) | decerebration rigidity | neurology | 2015 | experimental therapy | Poland | 9.6 |
| 461 | cord tissue (Wharton's jelly) | bilateral blindness | ophthalmology | 2015 | experimental therapy | Poland | 36.10 |
| 462 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 11/12 |
| 463 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 7.1 |
| 464 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 15.8 |
| 465 | cord tissue (Wharton's jelly) | ceroid lipofuscinosis | neurology | 2015 | experimental therapy | Poland | 5.1 |
| 466 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2015 | experimental therapy | Poland | 14.5 |
| 467 | cord tissue (Wharton's jelly) | ceroid lipofuscinosis | neurology | 2015 | experimental therapy | Poland | 7.10 |
| 468 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 3 |
| 469 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 7.1 |
| 470 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 13.1 |
| 471 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2015 | experimental therapy | Poland | 2.4 |
| 472 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 59.4 |
| 473 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 31.2 |
| 474 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 5.1 |
| 475 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 12.5 |
| 476 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 8.11 |
| 477 | cord tissue (Wharton's jelly) | delayed psychomotor development, deafness | neurology | 2015 | experimental therapy | Poland | 3.3 |
| 478 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61.5 |
| 479 | cord tissue (Wharton's jelly) | traumatic encephalopathy | neurology | 2015 | experimental therapy | Poland | 20.11 |
| 480 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 18.8 |
| 481 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 2.7 |
| 482 | cord tissue (Wharton's jelly) | adrenoleukodystrophy; encephalopathy | neurology | 2015 | experimental therapy | Poland | 23 |
| 483 | cord tissue (Wharton's jelly) | adrenoleukodystrophy | neurology | 2015 | experimental therapy | Poland | 11.11 |
| 484 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 40 |
| 485 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 26.1 |
| 486 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 37.1 |
| 487 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 58 |
| 488 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 35.6 |
| 489 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2015 | experimental therapy | Poland | 11/12 |
| 490 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 44.6 |
| 491 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2015 | experimental therapy | Poland | 15.8 |
| 492 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61.6 |
| 493 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2015 | experimental therapy | Poland | 66.2 |
| 494 | cord tissue (Wharton's jelly) | iatrogenic spinal cord injury | neurology | 2015 | experimental therapy | Poland | 17.2 |
| 495 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2015 | experimental therapy | Poland | 45.10 |
| 496 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 62 |
| 497 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 51.5 |
| 498 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 12.10 |
| 499 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 26.5 |
| 500 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 27 |
| 501 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 4.10 |
| 502 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 6.1 |
| 503 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 4.6 |
| 504 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 63.11 |
| 505 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 32.10 |
| 506 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 22 |
| 507 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2015 | experimental therapy | Poland | 33.3 |
| 508 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2015 | experimental therapy | Poland | 3.6 |
| 509 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2015 | experimental therapy | Poland | 2 |
| 510 | cord tissue (Wharton's jelly) | cerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 18.7 |
| 511 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 24.3 |
| 512 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 67.6 |
| 513 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 5.6 |
| 514 | cord tissue (Wharton's jelly) | polineuropathy | neurology | 2015 | experimental therapy | Poland | 74.2 |
| 515 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 37.6 |
| 516 | cord tissue (Wharton's jelly) | stroke | neurology | 2015 | experimental therapy | Poland | 62.8 |
| 517 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 58.10 |
| 518 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2015 | experimental therapy | Poland | 30.1 |
| 519 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2015 | experimental therapy | Poland | 10 |
| 520 | cord tissue (Wharton's jelly) | severe developmental delay | neurology | 2015 | experimental therapy | Poland | 1.1 |
| 521 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2015 | experimental therapy | Poland | 26.2 |
| 522 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 46.2 |
| 523 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 8.7 |
| 524 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2015 | experimental therapy | Poland | 8/12 |
| 525 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 6.6 |
| 526 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 48.7 |
| 527 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 21.4 |
| 528 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 9.9 |
| 529 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 13.4 |
| 530 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61.3 |
| 531 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 54 |
| 532 | cord tissue (Wharton's jelly) | intracranial injury | neurology | 2015 | experimental therapy | Poland | 24.3 |
| 533 | cord tissue (Wharton's jelly) | stroke | neurology | 2015 | experimental therapy | Poland | 54.9 |
| 534 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 24.7 |
| 535 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2015 | experimental therapy | Poland | 65.9 |
| 536 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2015 | experimental therapy | Poland | 18.8 |
| 537 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 34.4 |
| 538 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 1.6 |
| 539 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 14.10 |
| 540 | cord tissue (Wharton's jelly) | anterior ischemic optic neuropathy | ophthalmology | 2015 | experimental therapy | Poland | 54.10 |
| 541 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 16.9 |
| 542 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2015 | experimental therapy | Poland | 34.5 |
| 543 | cord tissue (Wharton's jelly) | cerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 26.1 |
| 544 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2015 | experimental therapy | Poland | 11.2 |
| 545 | cord tissue (Wharton's jelly) | adrenoleukodystrophy; encephalopathy | neurology | 2015 | experimental therapy | Poland | 8.4 |
| 546 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2014 | experimental therapy | Olsztyn | 60.10 |
| 547 | cord tissue (Wharton's jelly) | neuropathy | neurology | 2014 | experimental therapy | Poland | 23.6 |
| 548 | cord tissue (Wharton's jelly) | autism | neurology | 2014 | experimental therapy | Poland | 12.6 |
| 549 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2014 | experimental therapy | Poland | 6 |
| 550 | cord tissue (Wharton's jelly) | central motor coordination impairment after hypoxic ischaemia lesion at birth | neurology | 2014 | experimental therapy | Poland | 2.1 |
| 551 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2014 | experimental therapy | Poland | 24.1 |
| 552 | cord tissue (Wharton's jelly) | autism | neurology | 2014 | experimental therapy | Poland | 8.3 |
| 553 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2014 | experimental therapy | Poland | 6 |
| 554 | cord tissue (Wharton's jelly) | birth asphyxia; retinopathy | neurology | 2014 | experimental therapy | Poland | 11/12 |
| 555 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2014 | experimental therapy | Poland | 4.10 |
| 556 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2014 | experimental therapy | Poland | 15.10 |
| 557 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2013 | experimental therapy | Poland | 18.9 |
| 558 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2013 | experimental therapy | Poland | 2.1 |
| 559 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2013 | experimental therapy | Poland | 3.5 |
| 560 | cord tissue (Wharton's jelly) | acute myeloid leukemia | hematology | 2013 | experimental therapy | Poland | 3.5 |
| 561 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2013 | experimental therapy | Poland | 18.8 |
| 562 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2013 | experimental therapy | Poland | 17.5 |
| 563 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2012 | experimental therapy | Poland | 19.7 |
| 564 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2012 | experimental therapy | Poland | 7.1 |
| 565 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2012 | experimental therapy | Poland | 4.3 |
| 566 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2011 | experimental therapy | Poland | 17.2 |
| 567 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | France | 65 |
| 568 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Italy | 47 |
| 569 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Australia | 60 |
| 570 | peripheral blood | T-cell Acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Australia | 30 |
| 571 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Austria | 54 |
| 572 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Belgium | 57 |
| 573 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Belgium | 19 |
| 574 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Belgium | 71 |
| 575 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Belgium | 34 |
| 576 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Belgium | 55 |
| 577 | peripheral blood | prolymphocytic leukemia | hematology | 2017 | standard therapy | Belgium | 38 |
| 578 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Brazil | 12 |
| 579 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Canada | 57 |
| 580 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Canada | 56 |
| 581 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Canada | 67 |
| 582 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Canada | 63 |
| 583 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Croatia | 64 |
| 584 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Czech Republic | 48 |
| 585 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Czech Republic | 62 |
| 586 | peripheral blood | Langerhans Lymphohistiocytosis | hematology | 2017 | standard therapy | Czech Republic | 2 |
| 587 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Denmark | 63 |
| 588 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Estonia | 67 |
| 589 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Finland | 46 |
| 590 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | France | 68 |
| 591 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 65 |
| 592 | peripheral blood | no data | n/a | 2017 | standard therapy | France | 39 |
| 593 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | France | 43 |
| 594 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | France | 56 |
| 595 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 75 |
| 596 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 56 |
| 597 | peripheral blood | myeloma multiplex | hematology | 2017 | standard therapy | Germany | 44 |
| 598 | peripheral blood | chronic myeloproliferative neoplasm blast crisis | hematology | 2017 | standard therapy | Germany | 29 |
| 599 | peripheral blood | Common variable immunodeficiency, relapsed hemophagocytic syndrome | hematology | 2017 | standard therapy | Germany | 44 |
| 600 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 47 |
| 601 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Germany | 66 |
| 602 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 64 |
| 603 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 50 |
| 604 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 53 |
| 605 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 67 |
| 606 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Germany | 56 |
| 607 | peripheral blood | acute myelogenous leukemia with myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 64 |
| 608 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Germany | 29 |
| 609 | peripheral blood | diffuse large B-cell lymphoma | hematology | 2017 | standard therapy | Germany | 61 |
| 610 | peripheral blood | myeloma multiplex | hematology | 2017 | standard therapy | Germany | 56 |
| 611 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | Germany | 54 |
| 612 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 65 |
| 613 | peripheral blood | B-cell Chronic lymphoblastic leukemia | hematology | 2017 | standard therapy | Germany | 48 |
| 614 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 55 |
| 615 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Hungary | 47 |
| 616 | peripheral blood | β - Thalassemia Major | hematology | 2017 | standard therapy | India | 4 |
| 617 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Iran | 17 |
| 618 | peripheral blood | osteopetrosis | hematology | 2017 | standard therapy | Israel | 3 |
| 619 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 48 |
| 620 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 48 |
| 621 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 61 |
| 622 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 45 |
| 623 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Italy | 58 |
| 624 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 32 |
| 625 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 55 |
| 626 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 39 |
| 627 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Lithuania | 59 |
| 628 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Lithuania | 65 |
| 629 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Netherlands | 75 |
| 630 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Netherlands | 66 |
| 631 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Norway | 57 |
| 632 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 60 |
| 633 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 43 |
| 634 | peripheral blood | severe aplastic anaemia | hematology | 2017 | standard therapy | Poland | 14 |
| 635 | peripheral blood | Niemann–Pick disease | hematology | 2017 | standard therapy | Poland | 2 |
| 636 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 3 |
| 637 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 54 |
| 638 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 3 |
| 639 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 46 |
| 640 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 60 |
| 641 | peripheral blood | no data | hematology | 2017 | standard therapy | Poland | 39 |
| 642 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 64 |
| 643 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Poland | 47 |
| 644 | peripheral blood | myeloproliferative neoplasms | hematology | 2017 | standard therapy | Poland | 7 |
| 645 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 52 |
| 646 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 59 |
| 647 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 62 |
| 648 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 59 |
| 649 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 53 |
| 650 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 35 |
| 651 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 32 |
| 652 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Slovakia | 64 |
| 653 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Slovakia | 54 |
| 654 | peripheral blood | follicular CA | hematology | 2017 | standard therapy | South Africa | 42 |
| 655 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Spain | 63 |
| 656 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Spain | 20 |
| 657 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Sweden | 63 |
| 658 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Switzerland | 75 |
| 659 | peripheral blood | chronic myeloid leukemia | hematology | 2017 | standard therapy | Turkey | 29 |
| 660 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Turkey | 46 |
| 661 | peripheral blood | aplastic anaemia | hematology | 2017 | standard therapy | United Kingdom | 23 |
| 662 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | United Kingdom | 55 |
| 663 | peripheral blood | Hurler syndrome | hematology | 2017 | standard therapy | United Kingdom | 2 |
| 664 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | United Kingdom | 51 |
| 665 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 24 |
| 666 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 63 |
| 667 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 56 |
| 668 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 75 |
| 669 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 53 |
| 670 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 44 |
| 671 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 53 |
| 672 | peripheral blood | hemophagocytosis | hematology | 2017 | standard therapy | USA | 52 |
| 673 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | USA | 45 |
| 674 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 65 |
| 675 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | USA | 62 |
| 676 | peripheral blood | chłoniak nieziarniczy | hematology | 2017 | standard therapy | USA | 42 |
| 677 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 63 |
| 678 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 33 |
| 679 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 69 |
| 680 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 51 |
| 681 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 70 |
| 682 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 68 |
| 683 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 67 |
| 684 | peripheral blood | other myleofibrosis | hematology | 2017 | standard therapy | USA | 71 |
| 685 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 64 |
| 686 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 69 |
| 687 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 54 |
| 688 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 23 |
| 689 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | USA | 65 |
| 690 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 35 |
| 691 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 59 |
| 692 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 53 |
| 693 | peripheral blood | Lymphoblastic Lymphoma | hematology | 2016 | standard therapy | Italy | 33 |
| 694 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Australia | 62 |
| 695 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Australia | 61 |
| 696 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Australia | 51 |
| 697 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Australia | 62 |
| 698 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Austria | 60 |
| 699 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Austria | 41 |
| 700 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Austria | 61 |
| 701 | peripheral blood | no data | n/a | 2016 | standard therapy | Belgium | 30 |
| 702 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Belgium | 46 |
| 703 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Belgium | 56 |
| 704 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Belgium | 65 |
| 705 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Belgium | 9 |
| 706 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belgium | 44 |
| 707 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Brazil | 37 |
| 708 | peripheral blood | T-cell leukemia/lymphoma | hematology | 2016 | standard therapy | Canada | 31 |
| 709 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Canada | 13 |
| 710 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Canada | 47 |
| 711 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Columbia | 43 |
| 712 | peripheral blood | no data | n/a | 2016 | standard therapy | Czech Republic | 45 |
| 713 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 54 |
| 714 | peripheral blood | no data | n/a | 2016 | standard therapy | Czech Republic | 1 |
| 715 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Czech Republic | 56 |
| 716 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 49 |
| 717 | peripheral blood | no data | n/a | 2016 | standard therapy | Czech Republic | 59 |
| 718 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 37 |
| 719 | peripheral blood | myelodysplastic syndrome - RCMD | hematology | 2016 | standard therapy | Czech Republic | 32 |
| 720 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 60 |
| 721 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Denmark | 68 |
| 722 | peripheral blood | Fanconi anaemia | hematology | 2016 | standard therapy | Estonia | 7 |
| 723 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Estonia | 62 |
| 724 | peripheral blood | chronic myeloid leukemia | hematology | 2016 | standard therapy | Finland | 46 |
| 725 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2016 | standard therapy | Finland | 53 |
| 726 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 40 |
| 727 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 32 |
| 728 | peripheral blood | no data | n/a | 2016 | standard therapy | France | 59 |
| 729 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 47 |
| 730 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | France | 67 |
| 731 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 24 |
| 732 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 38 |
| 733 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 52 |
| 734 | peripheral blood | plasma cell disorder | hematology | 2016 | standard therapy | France | 47 |
| 735 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 67 |
| 736 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 32 |
| 737 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | France | 60 |
| 738 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 28 |
| 739 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | France | 59 |
| 740 | peripheral blood | myelofibrosis | hematology | 2016 | standard therapy | France | 67 |
| 741 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 56 |
| 742 | peripheral blood | plasma cell disorder | hematology | 2016 | standard therapy | France | 54 |
| 743 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 35 |
| 744 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 63 |
| 745 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 746 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 64 |
| 747 | peripheral blood | primary myelofibrosis | hematology | 2016 | standard therapy | Germany | 50 |
| 748 | peripheral blood | no data | n/a | 2016 | standard therapy | Germany | 71 |
| 749 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 46 |
| 750 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 29 |
| 751 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 50 |
| 752 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 13 |
| 753 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Germany | 32 |
| 754 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 32 |
| 755 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 756 | peripheral blood | T Cell Lymphoma/ NOS - Not otherwise specified | hematology | 2016 | standard therapy | Germany | 55 |
| 757 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 43 |
| 758 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 73 |
| 759 | peripheral blood | primary myelofibrosis | hematology | 2016 | standard therapy | Germany | 67 |
| 760 | peripheral blood | no data | n/a | 2016 | standard therapy | Germany | 17 |
| 761 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 762 | peripheral blood | chronic lymphocytic leukemia | hematology | 2016 | standard therapy | Germany | 62 |
| 763 | peripheral blood | myeloma multiplex | hematology | 2016 | standard therapy | Germany | 63 |
| 764 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 35 |
| 765 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 72 |
| 766 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 69 |
| 767 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 27 |
| 768 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 769 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 65 |
| 770 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 18 |
| 771 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 61 |
| 772 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 19 |
| 773 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 59 |
| 774 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 775 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 61 |
| 776 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 65 |
| 777 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 72 |
| 778 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 63 |
| 779 | peripheral blood | chronic myeloid leukemia | hematology | 2016 | standard therapy | Germany | 40 |
| 780 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 15 |
| 781 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 37 |
| 782 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 62 |
| 783 | peripheral blood | composite lymphoma | hematology | 2016 | standard therapy | Germany | 51 |
| 784 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 33 |
| 785 | peripheral blood | acute myelogenous leukemia M2/M4 | hematology | 2016 | standard therapy | Germany | 59 |
| 786 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 67 |
| 787 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 62 |
| 788 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 66 |
| 789 | peripheral blood | chronic myeloid leukemia | hematology | 2016 | standard therapy | Germany | 62 |
| 790 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Germany | 32 |
| 791 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Greece | 9 |
| 792 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Hungary | 57 |
| 793 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Hungary | 46 |
| 794 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Hungary | 20 |
| 795 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Ireland | 47 |
| 796 | peripheral blood | myelofibrosis | hematology | 2016 | standard therapy | Israel | 72 |
| 797 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Israel | 36 |
| 798 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Israel | 63 |
| 799 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 31 |
| 800 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 51 |
| 801 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Italy | 52 |
| 802 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 66 |
| 803 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 30 |
| 804 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Italy | 58 |
| 805 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 21 |
| 806 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 63 |
| 807 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Lithuania | 15 |
| 808 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Lithuania | 23 |
| 809 | peripheral blood | leukemia | hematology | 2016 | standard therapy | Lithuania | 53 |
| 810 | peripheral blood | no data | n/a | 2016 | standard therapy | Netherlands | 70 |
| 811 | peripheral blood | no data | n/a | 2016 | standard therapy | Netherlands | 69 |
| 812 | peripheral blood | no data | n/a | 2016 | standard therapy | Netherlands | 58 |
| 813 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Netherlands | 38 |
| 814 | peripheral blood | myelofibrosis | hematology | 2016 | standard therapy | Netherlands | 66 |
| 815 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Netherlands | 39 |
| 816 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | New Zealand | 59 |
| 817 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 56 |
| 818 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 43 |
| 819 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 18 |
| 820 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Poland | 31 |
| 821 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 54 |
| 822 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 18 |
| 823 | peripheral blood | adrenoleukodystrophy | metabolic | 2016 | standard therapy | Poland | 1 |
| 824 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 28 |
| 825 | peripheral blood | Wiskott-Aldrich syndrome | hematology | 2016 | standard therapy | Poland | 1 |
| 826 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 64 |
| 827 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 42 |
| 828 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 40 |
| 829 | peripheral blood | myelodysplastic syndrome - RAEB | hematology | 2016 | standard therapy | Poland | 56 |
| 830 | peripheral blood | chronic myelomonocytic leukemia, minimal residual disease | hematology | 2016 | standard therapy | Poland | 50 |
| 831 | peripheral blood | myeloma multiplex | hematology | 2016 | standard therapy | Poland | 51 |
| 832 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 30 |
| 833 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 46 |
| 834 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 55 |
| 835 | peripheral blood | myeloproliferative syndrome | hematology | 2016 | standard therapy | Poland | 52 |
| 836 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 44 |
| 837 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 65 |
| 838 | peripheral blood | myeloma multiplex | hematology | 2016 | standard therapy | Poland | 38 |
| 839 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 39 |
| 840 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 50 |
| 841 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 20 |
| 842 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Poland | 58 |
| 843 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 54 |
| 844 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 24 |
| 845 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 55 |
| 846 | peripheral blood | high-risk acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 5 |
| 847 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 19 |
| 848 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Portugal | 41 |
| 849 | peripheral blood | X-linked lymphoproliferative disease | hematology | 2016 | standard therapy | Russia | 12 |
| 850 | peripheral blood | primary Immunodeficiency | hematology | 2016 | standard therapy | Russia | 5 |
| 851 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Russia | 38 |
| 852 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Russia | 44 |
| 853 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Russia | 32 |
| 854 | peripheral blood | severe aplastic anaemia | hematology | 2016 | standard therapy | Russia | 18 |
| 855 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Serbia | 21 |
| 856 | peripheral blood | chronic lymphocytic leukemia | hematology | 2016 | standard therapy | Slovakia | 52 |
| 857 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Slovakia | 8 |
| 858 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Slovakia | 30 |
| 859 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Spain | 58 |
| 860 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Spain | 38 |
| 861 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Spain | 15 |
| 862 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Spain | 50 |
| 863 | peripheral blood | chronic lymphocytic leukemia | hematology | 2016 | standard therapy | Sweden | 61 |
| 864 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Sweden | 35 |
| 865 | peripheral blood | no data | n/a | 2016 | standard therapy | Sweden | 58 |
| 866 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Switzerland | 0.7 |
| 867 | peripheral blood | primary myelofibrosis | hematology | 2016 | standard therapy | Switzerland | 67 |
| 868 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Turkey | 55 |
| 869 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Turkey | 37 |
| 870 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Turkey | 38 |
| 871 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Turkey | 48 |
| 872 | peripheral blood | no data | n/a | 2016 | standard therapy | Turkey | 4 |
| 873 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Turkey | 51 |
| 874 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 58 |
| 875 | peripheral blood | refractory anemia with excess blasts | hematology | 2016 | standard therapy | United Kingdom | 62 |
| 876 | peripheral blood | aplastic anaemia | hematology | 2016 | standard therapy | United Kingdom | 23 |
| 877 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | United Kingdom | 18 |
| 878 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 62 |
| 879 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | United Kingdom | 68 |
| 880 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | United Kingdom | 20 |
| 881 | peripheral blood | SAA / Amyloidosis | hematology | 2016 | standard therapy | United Kingdom | 45 |
| 882 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 68 |
| 883 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 47 |
| 884 | peripheral blood | T-cell-prolymphocytic leukemia | hematology | 2016 | standard therapy | United Kingdom | 61 |
| 885 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | USA | 69 |
| 886 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 13 |
| 887 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Austria | 3 |
| 888 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Canada | 1 |
| 889 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Czech Republic | 68 |
| 890 | bone marrow | hyper IgM syndrome | hematology | 2017 | standard therapy | Finland | 2 |
| 891 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 76 |
| 892 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 65 |
| 893 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Hungary | 14 |
| 894 | bone marrow | myelodysplastic syndrome | hematology | 2017 | standard therapy | Italy | 60 |
| 895 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Italy | 38 |
| 896 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 59 |
| 897 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 10 |
| 898 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 55 |
| 899 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Lithuania | 1 |
| 900 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 6 |
| 901 | bone marrow | chronic granulomatous disease | hematology | 2017 | standard therapy | Poland | 2 |
| 902 | bone marrow | chronic granulomatous disease | hematology | 2017 | standard therapy | Poland | 4 |
| 903 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 16 |
| 904 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Russia | 30 |
| 905 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 59 |
| 906 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 1 |
| 907 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Turkey | 22 |
| 908 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Turkey | 6 |
| 909 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Turkey | 2 |
| 910 | bone marrow | thalassemia major | hematology | 2017 | standard therapy | Turkey | 11 |
| 911 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | United Kingdom | 10 |
| 912 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | United Kingdom | 9 |
| 913 | bone marrow | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 61 |
| 914 | bone marrow | leukemia | hematology | 2017 | standard therapy | USA | 40 |
| 915 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 67 |
| 916 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 21 |
| 917 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 57 |
| 918 | bone marrow | pure red cell aplasia | hematology | 2017 | standard therapy | USA | 5 |
| 919 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 60 |
| 920 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belarus | 15 |
| 921 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 67 |
| 922 | bone marrow | aplastic anaemia | hematology | 2016 | standard therapy | Austria | 20 |
| 923 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Belarus | 12 |
| 924 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belarus | 18 |
| 925 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belarus | 25 |
| 926 | bone marrow | biphenotypic leukemia | hematology | 2016 | standard therapy | Brazil | 27 |
| 927 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Canada | 11 |
| 928 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Croatia | 33 |
| 929 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 9 |
| 930 | bone marrow | Fanconi anaemia | hematology | 2016 | standard therapy | Estonia | 7 |
| 931 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Finland | 45 |
| 932 | bone marrow | severe aplastic anaemia | hematology | 2016 | standard therapy | France | 9 |
| 933 | bone marrow | severe aplastic anaemia | hematology | 2016 | standard therapy | France | 9 |
| 934 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 5 |
| 935 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 7 |
| 936 | bone marrow | osteopetrosis | metabolic | 2016 | standard therapy | Germany | 1 |
| 937 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Germany | 12 |
| 938 | bone marrow | Diamond-Balckfan anaemia | hematology | 2016 | standard therapy | Germany | 2 |
| 939 | bone marrow | juvenile myelomonocytic leukemia | hematology | 2016 | standard therapy | Germany | 3 |
| 940 | bone marrow | anaemia | hematology | 2016 | standard therapy | Germany | 16 |
| 941 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 6 |
| 942 | bone marrow | myelofibrosis | hematology | 2016 | standard therapy | Germany | 31 |
| 943 | bone marrow | myelodysplastic syndrome | hematology | 2016 | standard therapy | Hungary | 1 |
| 944 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Ireland | 39 |
| 945 | bone marrow | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 4 |
| 946 | bone marrow | no data | n/a | 2016 | standard therapy | Italy | 3 |
| 947 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 64 |
| 948 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 9 |
| 949 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 6 |
| 950 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 64 |
| 951 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 14 |
| 952 | bone marrow | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Italy | 17 |
| 953 | bone marrow | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Italy | 46 |
| 954 | bone marrow | anaemia | hematology | 2016 | standard therapy | Italy | 5 |
| 955 | bone marrow | DiGeorge syndrome | hematology | 2016 | standard therapy | Netherlands | 24 |
| 956 | bone marrow | Fanconi anaemia | hematology | 2016 | standard therapy | Netherlands | 41 |
| 957 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | New Zealand | 1 |
| 958 | bone marrow | no data | n/a | 2016 | standard therapy | Poland | 7 |
| 959 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Poland | 0.6 |
| 960 | bone marrow | severe aplastic anaemia / paroxymal nocturnal haemoglobinuria | hematology | 2016 | standard therapy | Poland | 17 |
| 961 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 5 |
| 962 | bone marrow | no data | n/a | 2016 | standard therapy | Poland | 33 |
| 963 | bone marrow | myeloproliferative syndrome | hematology | 2016 | standard therapy | Poland | 22 |
| 964 | bone marrow | high-risk acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 18 |
| 965 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Romania | 2 |
| 966 | bone marrow | osteopetrosis | metabolic | 2016 | standard therapy | Russia | 6 |
| 967 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Spain | 55 |
| 968 | bone marrow | myelodysplastic syndrome | hematology | 2016 | standard therapy | Spain | 56 |
| 969 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Turkey | 4 |
| 970 | bone marrow | Hurler syndrome | metabolic | 2016 | standard therapy | United Kingdom | 2 |
| 971 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 29 |
| {{$index+1}} | {{item.source}} | {{item.indication}} | {{item.area}} | {{item.year}} | {{item.therapy}} | {{item.country}} | {{item.age | number}} |